Comprehensive management guideline for breast cancer follow-up and concomitant diseases
10.3760/cma.j.issn.0253-3766.2019.01.006
- VernacularTitle: 乳腺癌随访及伴随疾病全方位管理指南
- Author:
Fei MA
1
;
Binghe XU
1
;
Zhimin SHAO
2
Author Information
1. Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2. Department of Breast Surgery, Tumour Hospital Affiliated to Fudan University, Shanghai 200032, China
- Collective Name:the Experts Committee of Chinese Guideline on the Breast Cancer Follow-up and Concomitant Diseases Comprehensive Management
- Publication Type:Guideline
- Keywords:
Breast cancer;
Follow-up;
Concomitant diseases;
Guideline
- From:
Chinese Journal of Oncology
2019;41(1):29-41
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, with the emphasis on breast cancer screening and the improvement of breast cancer diagnosis and treatment, five-year survival rate and the overall survival time of breast cancer patients have been significantly improved in China. The adverse events caused by patients′ age, changes in hormone levels or anti-cancer treatment during follow-up have become new challenges in the management of patients with breast cancer, not only affecting the quality of life, but also impacting disease recurrence and death. The management of patients should not be restricted to the diagnosis and treatment of breast cancer, but to a most comprehensive management. This could improve the therapeutic efficacy of anti-cancer treatment and the quality of life of patients. Based on the current landscape of treatment and follow-up of breast cancer patients in China, the experts committee drafted the "Comprehensive Management Guideline for Breast Cancer Follow-up and Concomitant Diseases" according to the literature and relevant guidelines. This guideline is composed of four parts: path diagram, follow-up management, concomitant diseases and adverse events management. It aims to standardize the long-term follow-up of breast cancer patients, guide clinicians to deal with the concomitant diseases and adverse events, and further improve the prognosis and quality of life of breast cancer patients in China.
